Collaborations

• SFB 1309 - Chemical Biology of Epigenetic Modifications, research on the development of novel sirtuin inhibitors; especially with Prof. Dr. Christian Ochsenfeld, Department of Chemistry, LMU Munich (quantum-chemical investigations) and Prof. Dr. Bernhard Küster, School of Life Sciences, Technical University of Munich (proteomics for target identification)
• Prof. Dr. Dr. Christian Grimm, Walther Straub Institute for Pharmacology and Toxicology, LMU Munich, Prof. Dr. Martin Biel, Department of Pharmacy, Molecular Pharmacology, LMU Munich, and Prof. Dr. Sandip Patel, University College London (UCL), Division of Biosciences, London (UK) (development of novel cation channel modulators)
• Prof. Dr. Manfred Jung, Pharmazeutisches Institut, Universität Freiburg (inhibitors of sirtuins and und histone deacetylases)
• Prof. Dr. Stefan Knapp, Structural Genomics Consortium, Goethe University of Frankfurt (kinase inhibitors, inhibitors of protein-protein-interactions, co-crystallizations)
• Prof. Dr. Angelika Vollmar, PD Dr. Stefan Zahler, Dr. Karin Bartel, Department of Pharmacy, LMU Munich (mechanisms of action of antitumor compounds)
• Dr. Simone Moser, Department of Pharmacy, LMU Munich (yeast three-hybrid screening for identification of targets of bioactive natural products)
• Prof. Dr. Wolfgang Frieß, Department of Pharmacy, LMU Munich (synthesis of new sugar-based excipients)
• Ass. Prof. Dr. Martin Giera, Metabolomics Group, Leiden University Medical Center (LUMC), Leiden (NL) (lipidomics for development of novel antiinflammatory drugs)
• Prof. Dr. Wolfgang Sippl, Institut for Pharmacy, University of Halle-Wittenberg (molecular modelling)
• Prof. Dr. Harald Steiner, Adolf-Butenandt Institute, LMU Munich (gamma-secretase)
• Dr. Frits Kamp, Adolf-Butenandt Institute, LMU Munich (gamma-secretase)
• Dr. Jens Peter von Kries, Leibniz-Institut für Molekulare Pharmakologie (FMP) (high throughput screening)
• Prof. Dr. Wanderley de Souza, Universidade Federal do Rio de Janeiro (Brasilien) (development of antiprotozoal drugs)
• Dr. Ulrike Binder, Prof. Dr. Cornelia Lass-Flörl, Section for Hygiene and Medicinal Microbiology (HMM), Medical University of Innsbruck, Austria (metabolism of pathogenic fungi and susceptibility to antifungal therapy)
• Prof. Dr. Erika von Mutius, Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, LMU München and Helmholtz Zentrum München, (development of antiasthmatic drugs)
• Prof. Dr. Robert Fürst, Pharmaceutical Biology, Goethe University of Frankfurt (antiinflammatory kinase inhibitors)
• Ass.-Prof. Dr. Fabio Gsaller, Division of Genomics and RNomics, Medical University of Innsbruck, Austria (mechanisms of fungal resistance)
• Prof. Dr. Oded Livnah, Department of Chemical Biology, Hebrew University of Jerusalem (Israel) (co-crystallization with kinases)
• Prof. Dr. Harald Schwalbe, Goethe University of Frankfurt (development of RNA-interacting drugs against Covid-19)
• Prof. Dr. Wolfgang Link, Instituto de Investigaciones Biomedicas „Alberto sols“ (CSIC-UAM), Department of Cancer Biology, Madrid, Spain (investigation of antitumor compounds)